Edgewise Therapeutics, Inc.
EWTX
$11.42
-$0.15-1.30%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 31.87M | 28.87M | 26.33M | 24.68M | 23.45M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 158.83M | 147.15M | 136.17M | 123.41M | 114.36M |
Operating Income | -158.83M | -147.15M | -136.17M | -123.41M | -114.36M |
Income Before Tax | -133.81M | -124.29M | -115.88M | -105.85M | -100.16M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -133.81 | -124.29 | -115.88 | -105.85 | -100.16 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -133.81M | -124.29M | -115.88M | -105.85M | -100.16M |
EBIT | -158.83M | -147.15M | -136.17M | -123.41M | -114.36M |
EBITDA | -156.76M | -145.18M | -134.29M | -121.58M | -112.81M |
EPS Basic | -1.45 | -1.49 | -1.53 | -1.54 | -1.57 |
Normalized Basic EPS | -0.90 | -0.93 | -0.96 | -0.96 | -0.98 |
EPS Diluted | -1.45 | -1.50 | -1.54 | -1.54 | -1.57 |
Normalized Diluted EPS | -0.90 | -0.93 | -0.96 | -0.96 | -0.98 |
Average Basic Shares Outstanding | 369.62M | 339.67M | 309.32M | 279.18M | 254.88M |
Average Diluted Shares Outstanding | 369.62M | 339.67M | 309.32M | 279.18M | 254.88M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |